as of 09-15-2026 3:51pm EST
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
| Founded: | 1971 | Country: | United States |
| Employees: | 70000 | City: | BURLINGTON |
| Market Cap: | 25.9B | IPO Year: | 2005 |
| Target Price: | $311.33 | AVG Volume (30 days): | 657.6K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 6.99 | EPS Growth: | 18.33 |
| 52 Week Low/High: | $244.52 - $341.80 | Next Earning Date: | 04-30-2026 |
| Revenue: | $13,951,700,000 | Revenue Growth: | 7.25% |
| Revenue Growth (this year): | 8.26% | Revenue Growth (next year): | 4.81% |
| P/E Ratio: | 46.35 | Index: | |
| Free Cash Flow: | 1.2B | FCF Growth: | +10.05% |
Director
Avg Cost/Share
$318.02
Shares
3,000
Total Value
$954,060.00
Owned After
6,563
SEC Form 4
President & CEO
Avg Cost/Share
$320.37
Shares
4,669
Total Value
$1,495,807.53
Owned After
102,565
SEC Form 4
EVP, Chief Marketing Officer
Avg Cost/Share
$306.74
Shares
924
Total Value
$283,427.76
Owned After
6,955.5
SEC Form 4
SVP, Chief Accounting Officer
Avg Cost/Share
$309.23
Shares
1,420
Total Value
$439,107.25
Owned After
1,770.219
EVP, Chief Legal Officer
Avg Cost/Share
$286.19
Shares
92
Total Value
$26,329.48
Owned After
3,904.457
SEC Form 4
EVP and President, Diagnostics
Avg Cost/Share
$286.19
Shares
234
Total Value
$66,968.46
Owned After
6,745.57
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ANDERSON KERRII B | LH | Director | Aug 17, 2026 | Sell | $318.02 | 3,000 | $954,060.00 | 6,563 | |
| Schechter Adam H | LH | President & CEO | Aug 11, 2026 | Sell | $320.37 | 4,669 | $1,495,807.53 | 102,565 | |
| Summy Amy B. | LH | EVP, Chief Marketing Officer | Aug 4, 2026 | Sell | $306.74 | 924 | $283,427.76 | 6,955.5 | |
| Wilkinson Peter J | LH | SVP, Chief Accounting Officer | Aug 3, 2026 | Sell | $309.23 | 1,420 | $439,107.25 | 1,770.219 | |
| Kyle Kathryn W | LH | EVP, Chief Legal Officer | Jul 2, 2026 | Sell | $286.19 | 92 | $26,329.48 | 3,904.457 | |
| Vaughn Bryan T | LH | EVP and President, Diagnostics | Jul 2, 2026 | Sell | $286.19 | 234 | $66,968.46 | 6,745.57 |
SEC 8-K filings with transcript text
Jul 30, 2026 · 100% conf.
1D
+1.60%
$312.08
Act: -2.01%
5D
+2.07%
$313.49
20D
+2.38%
$314.46
2 form8-kexhibit9912q26.htm
Document
Contact:Dewey Steadman - InvestorsRacquel White - Media
Investor@labcorp.comMedia@labcorp.com
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
•Results from operations for second quarter 2026 versus second quarter 2025:
◦Revenue: $3.73 billion vs. $3.53 billion, up 5.8%
◦Diluted EPS: $3.64 vs. $2.84, up 28.5%
◦Adjusted EPS: $4.99 vs. $4.35, up 14.9%
•Raised full-year enterprise revenue growth and adjusted EPS guidance:
◦Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint
◦Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint
•Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion
•Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence
•Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights
BURLINGTON, N.C., July 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.
“Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business,” said Adam Schechter, Chairman and CEO of Labcorp. “During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders.”
1
Labcorp continues to advance its strategic priorities:
Lead in specialty testing, with several advancements in Labcorp Oncology:
•Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity.
•Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense’s primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio.
•Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp’s Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence.
•Expanded nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca’s targeted therapy TRUQAP.
Be a partner of choice for health systems and regional/local laboratories:
•Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide.
•Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio.
•Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas.
Grow Consumer Health:
•Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.
•Introduced Canada's first at-home, self-collection test to measure women’s fertility-related hormones and men’s testosterone levels.
•Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health.
Shape our future through technology and innovation:
•Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic’s Aura platform.
•Enhanced the patient experience at Labcorp’s Patient Service Centers, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance.
2
Labcorp also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. The company also paid down $500.0 million in senior notes in June. On July 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record at the close of bus
Apr 30, 2026 · 100% conf.
1D
+1.90%
$261.69
Act: -0.49%
5D
+2.29%
$262.68
Act: +0.49%
20D
+2.52%
$263.26
Act: +1.43%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784333496.4269d8cf
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Feb 17, 2026 · 100% conf.
1D
-0.95%
$274.03
Act: +0.76%
5D
-1.80%
$271.69
Act: +3.78%
20D
-1.24%
$273.24
lh-202602170000920148false00009201482026-02-172026-02-17
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 17, 2026 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated February 17, 2026 issued by Labcorp titled “Labcorp Announces 2025 Fourth Quarter and Full Year Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: February 17, 2026By:/s/ KATHRYN W. KYLE Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary
Oct 28, 2025
lh-202510280000920148false00009201482025-10-282025-10-28
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2025 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated October 28, 2025 issued by Labcorp titled “Labcorp Announces 2025 Third Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: October 28, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
Jul 24, 2025
lh-202507240000920148false00009201482025-07-242025-07-24
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 24, 2025 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated July 24, 2025 issued by Labcorp titled “Labcorp Announces 2025 Second Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: July 24, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
Apr 29, 2025
lh-202504290000920148false00009201482025-04-292025-04-29
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 29, 2025 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated April 29, 2025 issued by Labcorp titled “Labcorp Announces 2025 First Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: April 29, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
Feb 6, 2025
lh-202502060000920148false00009201482025-02-062025-02-06
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 6, 2025 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated February 6, 2025 issued by Labcorp titled “Labcorp Announces 2024 Fourth Quarter and Full Year Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: February 6, 2025By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
Oct 24, 2024
lh-20241024October 24, 20240000920148false00009201482024-10-242024-10-24
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 24, 2024 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 24, 2024 issued by Labcorp titled "Labcorp Announces 2024 Third Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 24, 2024
Aug 1, 2024
lh-20240801August 01, 20240000920148false00009201482024-08-012024-08-01
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
August 01, 2024 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated August 1, 2024 issued by Labcorp titled "Labcorp Announces 2024 Second Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
August 01, 2024
Apr 25, 2024
lh-20240425April 25, 20240000920148false00009201482024-04-252024-04-25
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 25, 2024 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 25, 2024 issued by Labcorp titled "Labcorp Announces 2024 First Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 25, 2024
Feb 15, 2024
lh-20240215February 15, 20240000920148FALSE00009201482024-02-152024-02-15
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 15, 2024 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 15, 2024 issued by Labcorp
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 15, 2024
Oct 26, 2023
lh-20231026October 26, 20230000920148false00009201482023-10-262023-10-26
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 26, 2023 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 26, 2023 issued by Labcorp titled "Labcorp Announces 2023 Third Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 26, 2023
Jul 27, 2023
lh-20230727July 27, 20230000920148false00009201482023-07-272023-07-27
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 27, 2023 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated July 27, 2023 issued by Labcorp titled "Labcorp Announces 2023 Second Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
July 27, 2023
Apr 25, 2023
lh-20230425April 25, 20230000920148false00009201482023-04-252023-04-25
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 25, 2023 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 25, 2023 issued by Labcorp titled "Labcorp Announces 2023 First Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 25, 2023
Feb 16, 2023
lh-20230216February 16, 20230000920148FALSE00009201482023-02-162023-02-16
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 16, 2023 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 16, 2023 issued by Labcorp
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 16, 2023
Oct 27, 2022
lh-20221027October 27, 20220000920148false00009201482022-10-272022-10-27
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 27, 2022 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 27, 2022 issued by Labcorp titled "Labcorp Announces 2022 Third Quarter Results"
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 27, 2022
Jul 28, 2022
lh-20220728July 28, 20220000920148false00009201482022-07-282022-07-28
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 28, 2022 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
On July 28, 2022, Laboratory Corporation of America Holdings (Labcorp) issued a press release reporting financial results for the three months ended June 30, 2022. A copy of Labcorp’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 7.01Regulation FD Disclosure
On July 28, 2022, Labcorp announced that its board of directors authorized Labcorp to pursue a spin-off of its wholly owned Clinical Development business, which includes the parts of its Drug Development segment focused on providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations. A copy of Labcorp’s press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated July 28, 2022 issued by Labcorp titled "Labcorp Announces 2022 Second Quarter Results"
Exhibit 99.2Press Release dated July 28, 2022 issued by Labcorp titled "Labcorp to Spin Off Clinical Development Business"
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
July 28, 2022
Apr 28, 2022
lh-20220428April 28, 20220000920148false00009201482022-04-282022-04-28
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 28, 2022 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated April 28, 2022 issued by Labcorp
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
April 28, 2022
Feb 10, 2022
lh-20220210February 10, 20220000920148FALSE00009201482022-02-102022-02-10
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 10, 2022 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135313-3757370 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated February 10, 2022 issued by Labcorp
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
February 10, 2022
Oct 28, 2021
lh-20211028October 28, 20210000920148false00009201482021-10-282021-10-28
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2021 (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act. Title of Each Class Trading Symbol Name of exchange on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits.
ExhibitExhibit Name Exhibit 99.1Press Release dated October 28, 2021 issued by Labcorp
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
By:/s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
October 28, 2021
See how LH stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LH Laboratory Corporation of America Holdings - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.